Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Klinikum Magdeburg · Jena University Hospital · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
849
total citations
- FWCI
- 70.42
- Percentile
- 100%
- References
- 35
Citations per year
Authors
17- AHAndreas HochhausCorresponding
Klinikum Magdeburg, Jena University Hospital
- GSGiuseppe Saglio
University of Turin
- TPTimothy P. Hughes
South Australian Health and Medical Research Institute, University of Adelaide, South Australia Pathology
- RARichard A. Larson
University of Chicago
- DKD-W Kim
Catholic University of Korea, Seoul St. Mary's Hospital
Topics & keywords
Topics
Keywords
- Nilotinib
- Medicine
- Imatinib
- Internal medicine
- Myeloid leukemia
- Randomized controlled trial
- Imatinib mesylate
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.